PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.
McCormack, S; Ramjee, G; Kamali, A; Rees, H; Crook, AM; Gafos, M; Jentsch, U; Pool, R; Chisembele, M; Kapiga, S; Mutemwa, R; Vallely, A; Palanee, T; Sookrajh, Y; Lacey, CJ; Darbyshire, J; Grosskurth, H; Profy, A; Nunn, A; Hayes, R; Weber, J; (2010) PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet, 376 (9749). pp. 1329-37. ISSN 0140-6736 DOI: 10.1016/S0140-6736(10)61086-0
|PDF - Published Version |
Available under License Creative Commons Attribution Non-commercial No Derivatives.
Download (545Kb) | Preview
Innovative prevention strategies for HIV-1 transmission are urgently needed. PRO2000 vaginal gel was efficacious against HIV-1 transmission in studies in macaques; we aimed to assess efficacy and safety of 2% and 0·5% PRO2000 gels against vaginal HIV-1 transmission in women in sub-Saharan Africa.
Item downloaded times since 17 Oct 2011 15:06.
Actions (login required)